Industry attention is splitting between in‑vivo CAR‑T strategies that aim to reprogram T cells inside patients and biomarker research that predicts ex‑vivo CAR‑T outcomes. In‑vivo CAR‑T platforms—using viral vectors or non‑integrating lipid nanoparticles—promise off‑the‑shelf scalability but carry known risks like insertional mutagenesis; early human studies from EsoBiotec and Kelonia have shown tumor clearance signals in multiple myeloma. Complementing delivery advances, a separate study identified predictive biomarkers for CAR‑T success across hematologic malignancies, offering tools to stratify patients and optimize manufacturing and dosing. Together, these reports highlight parallel efforts to increase CAR‑T accessibility: one by simplifying manufacturing and delivery, the other by improving patient selection and outcome prediction.